Focused On-demand Library for Disintegrin and metalloproteinase domain-containing protein 10

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

CDw156; Kuzbanian protein homolog; Mammalian disintegrin-metalloprotease

Alternative UPACC:

O14672; B4DU28; Q10742; Q92650


Disintegrin and metalloproteinase domain-containing protein 10, also known as ADAM10, plays a pivotal role in cellular processes including proteolytic release of cell-surface proteins and cleavage of amyloid precursor protein (APP). Its activity is crucial for the development and maturation of various tissues, including the vasculature and the nervous system. ADAM10's involvement in cleaving cell adhesion molecules and cytokine receptors underscores its multifaceted role in biological systems.

Therapeutic significance:

ADAM10's link to diseases such as Reticulate acropigmentation of Kitamura and Alzheimer disease 18 highlights its potential as a therapeutic target. Its role in the proteolytic processing of APP and contribution to the amyloidogenic pathway suggest that modulating ADAM10 activity could offer new avenues for treating Alzheimer's disease. Understanding the role of ADAM10 could open doors to potential therapeutic strategies for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.